BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16986125)

  • 1. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
    Trent JC; Ramdas L; Dupart J; Hunt K; Macapinlac H; Taylor E; Hu L; Salvado A; Abbruzzese JL; Pollock R; Benjamin RS; Zhang W
    Cancer; 2006 Oct; 107(8):1898-908. PubMed ID: 16986125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
    Cullinane C; Dorow DS; Kansara M; Conus N; Binns D; Hicks RJ; Ashman LK; McArthur GA; Thomas DM
    Cancer Res; 2005 Nov; 65(21):9633-6. PubMed ID: 16266981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.
    Dupart JJ; Trent JC; Lee HY; Hess KR; Godwin AK; Taguchi T; Zhang W
    Mol Cancer; 2009 Nov; 8():99. PubMed ID: 19903356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography.
    Prenen H; Deroose C; Vermaelen P; Sciot R; Debiec-Rychter M; Stroobants S; Mortelmans L; Schöffski P; Van Oosterom A
    Anticancer Res; 2006; 26(2A):1247-52. PubMed ID: 16619531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early response assessment in gastrointestinal stromal tumors with FDG PET scan 24 hours after a single dose of imatinib.
    Shinto A; Nair N; Dutt A; Baghel NS
    Clin Nucl Med; 2008 Jul; 33(7):486-7. PubMed ID: 18580237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
    McAuliffe JC; Hunt KK; Lazar AJ; Choi H; Qiao W; Thall P; Pollock RE; Benjamin RS; Trent JC
    Ann Surg Oncol; 2009 Apr; 16(4):910-9. PubMed ID: 18953611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.
    Simon S; Grabellus F; Ferrera L; Galietta L; Schwindenhammer B; Mühlenberg T; Taeger G; Eilers G; Treckmann J; Breitenbuecher F; Schuler M; Taguchi T; Fletcher JA; Bauer S
    Cancer Res; 2013 Jun; 73(12):3661-70. PubMed ID: 23576565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.
    Fan R; Zhong J; Zheng S; Wang Z; Xu Y; Li S; Zhou J; Yuan F
    Clin Exp Med; 2015 May; 15(2):137-44. PubMed ID: 24706111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.
    Liu Y; Perdreau SA; Chatterjee P; Wang L; Kuan SF; Duensing A
    Cancer Res; 2008 Nov; 68(21):9015-23. PubMed ID: 18974147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
    Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
    J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S; Duensing A; Demetri GD; Fletcher JA
    Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Establishment and pathologic analysis of imatinib-resistant gastrointestinal stromal tumor xenografts].
    Zheng S; Wang XJ; Jia J; Pan YL; Tao DY; Lu HS; Huang KE
    Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):176-80. PubMed ID: 22800481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT imaging of gastrointestinal stromal tumor with calcified peritoneal implants after imatinib therapy.
    Eslamy HK; Quon A
    Clin Nucl Med; 2008 Dec; 33(12):864-5. PubMed ID: 19033789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging.
    Zincirkeser S; Sevinc A; Kalender ME; Camci C
    World J Gastroenterol; 2007 Apr; 13(15):2261-2. PubMed ID: 17465516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.